RemSleep Holdings Inc.

Going-concern sleep-apnea micro-cap with an $18.3M accumulated deficit and catastrophic margins, just beginning to commercialize its DeltaWave product.

Strengths

• FDA 510(k) clearance broadened and Medicare PDAC coding obtained for DeltaWave launch
• Gross margin ~24% positive on a small product line

Risks

• Net margin -180x and operating margin -166x on negligible revenue ($16.7k); ROE -94x
• Going concern, $18.3M accumulated deficit, ongoing dilutive convertible-note funding
• Pre-scale commercial model dependent on unproven DME sales ramp

Notable findings

• Going concernThese conditions and the ability to successfully resolve these factors over the next twelve months raise substantial doubt about the Company’s ability to continue as a going concern
• Exec changeRecent 8-K item 5.02 8-K ↗
• Net lossNet loss (net margin -18062.9%)
• Weak liquidityCurrent ratio 0.89 (<1)
• Chronic dilutionShare count +28%/yr over 3y (dilution, book value/share -99%)
• Revenue declineRevenue -40.4% YoY